SINUS-24 SINUS-52

DUPIXENT (300 mg Q2W + INCS) reduced polyp burden as early as Week 4, sustained through Week 52 in SINUS-52 as compared to placebo.4

There was a reduction in bilateral NPS as follows:

Nasal polyp score (NPS), the sum of right and left nostril scores (range 0 to 4 for each nostril, range 0 to 8 in total) as evaluated by nasal endoscopy: reduced score indicates improvement.1

INCS, intranasal corticosteroid; LSM, least squares mean; Q2W, once every 2 weeks.

See what polyp reduction looks like with DUPIXENT